ArticleScientific reports2026
Cystatin C regulates cell division in primary central nervous system lymphoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary central nervous system lymphoma (PCNSL) is associated with cerebral inflammation characterized by elevated neutrophils, monocytes, platelets, and lymphocytes. However, the comprehensive profile of inflammation-related molecules in PCNSL remains unclear. In this study, we conducted proteomic analysis of PCNSL tissue compared with normal brain to identify factors influencing neuroinflammation and potential therapeutic targets. In contrast to the general elevation of inflammatory molecules, cystatin C (Cyst C) showed markedly reduced expression. This result was confirmed by western blotting and mRNA analysis. Immunohistochemistry revealed widespread Cyst C positivity in glial cells of the normal brain, whereas PCNSL tissue was dominated by Cyst C-negative B cells. To further investigate its role, cultured PCNSL cells were treated with recombinant human Cyst C. Treatment reduced viable cell counts in a dose- and time-dependent manner over 4 days without inducing cell death, indicating inhibition of cell division. Immunohistochemistry demonstrated that Cyst C increased p21 expression and decreased cyclin-dependent kinase 1 and Cyclin B. These findings identify Cyst C as a regulator of PCNSL cell division, highlighting it as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.